Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.
Læs hele meddelelsen:
https://www.zealandpharma.com/zealand-news
Læs hele meddelelsen:
https://www.zealandpharma.com/zealand-news